Literature Review of Percutaneous Stenting for Palliative Treatment of Malignant Superior Vena Cava Syndrome (SVCS)
Published by Elsevier Inc..
RATIONALE AND OBJECTIVES: To assess the efficacy and safety of percutaneous stenting for the palliative treatment of malignant superior vena cava syndrome (SVCS).
METHODS AND MATERIALS: Literature review of retrospective studies was performed regarding direct procedural complications (fatal and non-fatal), clinical effectiveness, and patency rates (primary and secondary) of percutaneous transluminal stenting for the palliative treatment of malignant SVCS. Pooled rates and 95% confidence intervals were calculated for fatal complications, non-fatal complications, clinical effectiveness, primary patency, and secondary patency. Pooled rates were presented overall and by stent types (Wallstent, Nitinol stents, Steel stents and Stent Graft). Odds ratios and 95% confidence intervals were calculated to compare rates by stent type.
RESULTS: Overall fatal complications rate was 1.46%, 95% CI [0.91 -2.23], non-fatal complications rate was 8.28%, 95% CI [6.91 -9.83], clinical effectiveness was 90.50%, 95% CI [88.86 -91.97], primary patency rate was 86.18%, 95% CI [84.06-88.12], secondary patency rate was 94.05 %, 95% CI [91.82 -95.82]. Primary patency rate of the Wallstent group was 83.38%, 95% CI [79.34 -86.90], and significantly higher for the Nitinol group 94.87%, 95% CI [87.40 -98.60], OR = 3.67, p = 0.01, and for the Stent Graft group 96.10%, 95% CI [89.00 -99.20], OR = 4.92, p = 0.01. Secondary patency rate for the Wallstent group was 93.33%, 95% CI [88.87 -96.40] and significantly lower for the Steel group 77.42%, 95% CI [58.90 -90.41], OR = 0.25, p = 0.01.
CONCLUSION: Percutaneous stenting is a safe option for palliative treatment of patients with malignant SVCS with greater than 90% of patients experiencing immediate relief of symptoms, low rates of fatal complications (1.46%) and high patency rates (86.18% primary patency and 94.05% secondary patency).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 Suppl 4 |
|---|---|
| Enthalten in: |
Academic radiology - 29 Suppl 4(2022) vom: 10. Apr., Seite S110-S120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Léon, David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
12597-69-2 |
|---|
| Anmerkungen: |
Date Completed 26.04.2022 Date Revised 04.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.acra.2021.08.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331436639 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331436639 | ||
| 003 | DE-627 | ||
| 005 | 20231225213447.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.acra.2021.08.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331436639 | ||
| 035 | |a (NLM)34602363 | ||
| 035 | |a (PII)S1076-6332(21)00374-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Léon, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Literature Review of Percutaneous Stenting for Palliative Treatment of Malignant Superior Vena Cava Syndrome (SVCS) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2022 | ||
| 500 | |a Date Revised 04.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Elsevier Inc. | ||
| 520 | |a RATIONALE AND OBJECTIVES: To assess the efficacy and safety of percutaneous stenting for the palliative treatment of malignant superior vena cava syndrome (SVCS) | ||
| 520 | |a METHODS AND MATERIALS: Literature review of retrospective studies was performed regarding direct procedural complications (fatal and non-fatal), clinical effectiveness, and patency rates (primary and secondary) of percutaneous transluminal stenting for the palliative treatment of malignant SVCS. Pooled rates and 95% confidence intervals were calculated for fatal complications, non-fatal complications, clinical effectiveness, primary patency, and secondary patency. Pooled rates were presented overall and by stent types (Wallstent, Nitinol stents, Steel stents and Stent Graft). Odds ratios and 95% confidence intervals were calculated to compare rates by stent type | ||
| 520 | |a RESULTS: Overall fatal complications rate was 1.46%, 95% CI [0.91 -2.23], non-fatal complications rate was 8.28%, 95% CI [6.91 -9.83], clinical effectiveness was 90.50%, 95% CI [88.86 -91.97], primary patency rate was 86.18%, 95% CI [84.06-88.12], secondary patency rate was 94.05 %, 95% CI [91.82 -95.82]. Primary patency rate of the Wallstent group was 83.38%, 95% CI [79.34 -86.90], and significantly higher for the Nitinol group 94.87%, 95% CI [87.40 -98.60], OR = 3.67, p = 0.01, and for the Stent Graft group 96.10%, 95% CI [89.00 -99.20], OR = 4.92, p = 0.01. Secondary patency rate for the Wallstent group was 93.33%, 95% CI [88.87 -96.40] and significantly lower for the Steel group 77.42%, 95% CI [58.90 -90.41], OR = 0.25, p = 0.01 | ||
| 520 | |a CONCLUSION: Percutaneous stenting is a safe option for palliative treatment of patients with malignant SVCS with greater than 90% of patients experiencing immediate relief of symptoms, low rates of fatal complications (1.46%) and high patency rates (86.18% primary patency and 94.05% secondary patency) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Malignant SVC Syndrome | |
| 650 | 4 | |a SVC Stenting | |
| 650 | 7 | |a Steel |2 NLM | |
| 650 | 7 | |a 12597-69-2 |2 NLM | |
| 700 | 1 | |a Rao, Sishir |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Sheth, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Yevich, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Ahrar, Kamran |e verfasserin |4 aut | |
| 700 | 1 | |a Huynh, Tam |e verfasserin |4 aut | |
| 700 | 1 | |a Pisimisis, George |e verfasserin |4 aut | |
| 700 | 1 | |a Kuban, Joshua D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Academic radiology |d 1995 |g 29 Suppl 4(2022) vom: 10. Apr., Seite S110-S120 |w (DE-627)NLM087676818 |x 1878-4046 |7 nnns |
| 773 | 1 | 8 | |g volume:29 Suppl 4 |g year:2022 |g day:10 |g month:04 |g pages:S110-S120 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.acra.2021.08.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 Suppl 4 |j 2022 |b 10 |c 04 |h S110-S120 | ||